Fluoroquinolones (FQ) such as enrofloxacin (ENR) and marbofloxacin (MAR) are broad-spectrum antibacterial agents active against many Gram-negative and Gram-positive bacteria as well as mycoplasmas (1). Mycoplasma hyopneumoniae (Mh) is the primary causative agent of enzootic pneumonia in swine, prevalent in most swine producing areas of the world, and causes significant economic losses to the swine industry (2). Both ENR and MAR are recommended for the treatment of enzootic pneumonia (EP) because of their mycoplasmacidal activity (2). High in vitro activity of ENR against Mh was reported previously (3). ENR and MAR showed good clinical efficacy in the treatment of EP (4, 5). Mh is extremely difficult to isolate because of its slow growth and interference with other swine mycoplasmas (2).
展开▼
